On the contrary, inhibition of IL‐17 has been considered an important therapeutic target in patients with psoriasis and concomitant MS since the pathophysiology of psoriasis implicates mechanisms perturbing the IL‐23/Th17 axis. This evidence concerns the gene IL17A and psoriasis.